Drug intelligence / Profile preview

insulin lispro + insulin peglispro

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

This is a combination of insulin lispro (a rapid-acting insulin analog) and insulin peglispro (a long-acting basal insulin). Insulin peglispro is a modified version of insulin lispro with a polyethylene glycol polymer attached, giving it a longer duration of action. The combination was studied for treatment of type 1 diabetes, showing improved glycemic control with lower HbA1c levels compared to insulin glargine, but development was discontinued due to safety concerns including elevated liver enzymes and triglycerides.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin lispro + insulin peglispro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin lispro + insulin peglispro.

Explore the full profile